PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Cisplatin vs Carboplatin: Only Two Comparisons Reach High-Certainty Evidence

cisplatincarboplatinplatinum chemotherapyumbrella meta-analysisurothelial carcinomaovarian cancerNSCLCSCLCcervical cancergerm cell tumorshead and neck cancerGRADEtoxicityoncology pharmacy Oncology

Background Information

Cisplatin outperforms carboplatin in certain cancers but with higher toxicity.

The study clarifies the comparative efficacy and safety of cisplatin and carboplatin across several solid tumor types. Cisplatin shows higher response rates in urothelial and cervical cancer, but also higher ototoxicity and nephrotoxicity. No survival differences in most cancers. The data is high-certainty for some cancers but overall shows moderate to low-certainty evidence, restricting definitive conclusions on survival benefits. Cisplatin is more effective in specific cancers but with higher toxicity risk.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Jiménez-Labaig P, Mirallas O, Pereira F, Sanz J, Felip E, Rodon J, Colombo N, Galsky MD, Harrington KJ

Citation: Jiménez-Labaig P, Mirallas O, Pereira F, et al. Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors: An Umbrella Meta-Analysis. JAMA network open. 2026;9(9):e2634287. doi:10.1001/jamanetworkopen.2026.34287

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.